Frits Van Rhee, MD, PhD, MRCP

Research Program: Cancer Therapeutics Faculty Rank: Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Internal Medicine

Cancer Research Interest

• Disease Site Focus: Multiple Myeloma
• Research Focus Area: Treatment, Diagnosis/ Prognosis
• Type of Research: Clinical, Basic

Contact Information

• Email Address: VANRHEEFRITS@UAMS.EDU
• Profiles Research Networking Software: View Profile

Open Clinical Trials

• “Expanded Access Program for Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody” (NCT03763370)
• “M22-947: A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Myeloma Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma” (NCT05259839)
• “Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel that is Nonconforming for Commercial Release” (NCT04771078)
• “A Phase II, Single-Arm Open-Label Multi-Center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease” (NCT03933904)
• “A Phase II Trial for the Treatment of POEMS Syndrome with Daratumumab” (NCT04396496)

Publications

• Mazahreh F, Mazahreh L, Schinke C, [et al., including Van Rhee F]. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood advances. 2023. PMID: 36857755.
• Roy Choudhury S, Byrum SD, Alkam D, [et al., including Van Rhee F]. Expression of integrin ?-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics. Clinical epigenetics. 2023 15(1):18. PMID: 36737807. PMCID: PMC9898982.
• Al Hadidi S, Dongarwar D, Schinke C, [et al., including van Rhee F]. Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma. Clinical hematology international. 2023. PMID: 36737587.
• Al Hadidi S, van Rhee F. Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023:JCO2202098. PMID: 36626704.
• Al Hadidi S, Szabo A, Esselmann J, [et al., including van Rhee F]. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone marrow transplantation. 2022. PMID: 36550200.
• Garg TK, Garg S, Miousse IR, [et al., including van Rhee F]. Gamma-Tocotrienol Modulates Total-Body Irradiation-Induced Hematopoietic Injury in a Nonhuman Primate Model. International journal of molecular sciences. 2022 23(24). PMID: 36555814. PMCID: PMC9784560.
• Ajore R, Niroula A, Pertesi M, [et al., including van Rhee F]. Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk. Nature communications. 2022 13(1):7725. PMID: 36513657. PMCID: PMC9747780.
• Thompson MA, Boccadoro M, Leleu X, [et al., including van Rhee F]. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. Clinical lymphoma, myeloma & leukemia. 2022. PMID: 36641358.
• Mohan M, Rein LE, Thalambedu N, [et al., including van Rhee F]. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. American journal of hematology. 2022 97(12):E451-E453. PMID: 36097868.
• Pierson SK, Katz L, Williams R, [et al., including van Rhee F]. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. Nature communications. 2022 13(1):7236. PMID: 36433996. PMCID: PMC9700691.
• Al Hadidi S, Dongarwar D, Salihu H, [et al., including van Rhee F]. Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. Clinical hematology international. 2022 4(3):117-120. PMID: 36131130. PMCID: PMC9492819.
• van Rhee F. Case 16-2022: A Man with Fevers, Night Sweats, and a Mediastinal Mass. The New England journal of medicine. 2022 387(8):762-763. PMID: 36001726.
• Schinke C, Poos AM, Bauer MA, [et al., including van Rhee F]. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single cell level. Blood advances. 2022. PMID: 35977111. PMCID: PMC9647426.
• Rasche L, Schinke C, Maura F, [et al., including van Rhee F]. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nature communications. 2022 13(1):4517. PMID: 35922426. PMCID: PMC9349320.
• Alqazaqi R, Schinke C, Thanendrarajan S, [et al., including van Rhee F]. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA network open. 2022 5(8):e2228877. PMID: 36018590. PMCID: PMC9419017.
• Nishimura Y, Nishimura MF, Fajgenbaum DC, [et al., including van Rhee F]. Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis. EJHaem. 2022 3(3):748-753. PMID: 36051051. PMCID: PMC9421978.
• Gai D, Chen JR, Stewart JP, [et al., including van Rhee F]. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. The Journal of clinical investigation. 2022. PMID: 35881476. PMCID: PMC9479617.
• van Rhee F, Rosenthal AL, Kanhai K, [et al.]. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood advances. 2022. PMID: 35793409. PMCID: PMC9631655.
• Sudha P, Ahsan A, Ashby C, [et al., including van Rhee F]. MGP Panel is a comprehensive targeted genomics panel for molecular profiling of multiple myeloma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022. PMID: 35522533. PMCID: PMC9250632.
• Fajgenbaum DC, Pierson SK, Kanhai K, [et al., including van Rhee F]. The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry. British journal of haematology. 2022. PMID: 35507638. PMCID: PMC9544190.
• Al Hadidi S, Zangari M, van Rhee F. Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions. JAMA oncology. 2022. PMID: 35482363.
• Van Rhee F. Nearly 70 years later: the continued unraveling of Castleman Disease. Haematologica. 2022. PMID: 35484683. PMCID: PMC9827149.
• Mohan M, Becnel MR, Shah UA, [et al., including van Rhee F]. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. American journal of hematology. 2022. PMID: 35472167.
• Al Hadidi S, Schinke C, Thanendrarajan S, [et al., including van Rhee F]. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA network open. 2022 5(4):e228161. PMID: 35442451. PMCID: PMC9021907.
• Abushukair H, Syaj S, Ababneh O, [et al., including van Rhee F]. First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis. American journal of hematology. 2022. PMID: 35358350.
• Larsen K, Spencer H, Mohan M, [et al., including van Rhee F]. Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. Journal of clinical medicine. 2022 11(6). PMID: 35329966. PMCID: PMC8955129.
• Mohan M, Gundarlapalli S, Szabo A, [et al., including van Rhee F]. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. American journal of hematology. 2022. PMID: 35285981.
• Ajore R, Niroula A, Pertesi M, [et al., including van Rhee F]. Functional dissection of inherited non-coding variation influencing multiple myeloma risk. Nature communications. 2022 13(1):151. PMID: 35013207. PMCID: PMC8748989.
• Lang E, Sande B, Brodkin S, van Rhee F. Idiopathic multicentric Castleman disease treated with siltuximab for 15?years: a case report. Therapeutic advances in hematology. 2022 13:20406207221082552. PMID: 35251585. PMCID: PMC8894931.
• Rossi JF, Chiang HC, Lu ZY, [et al., including van Rhee F]. Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling. Frontiers in immunology. 2022 13:919489. PMID: 35928820. PMCID: PMC9345304.
• Mikulasova A, Kent D, Trevisan-Herraz M, [et al., including van Rhee F]. Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome research. 2021. PMID: 34933939. PMCID: PMC9341503.
• Roy Choudhury S, Ashby C, Zhan F, van Rhee F. Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients. Cancers. 2021 13(24). PMID: 34944968. PMCID: PMC8699806.
• Baker D, Bimali M, Carrillo L, [et al., including Van Rhee F]. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 106(12):3215-3218. PMID: 34847659. PMCID: PMC8634177.
• Mohan M, Kendrick S, Szabo A, [et al., including van Rhee F]. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood advances. 2021. PMID: 34807986. PMCID: PMC8945288.
• Pierson SK, Shenoy S, Oromendia AB, [et al., including van Rhee F]. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood advances. 2021 5(17):3445-3456. PMID: 34438448. PMCID: PMC8525223.
• Baker D, Bimali M, Carrillo L, [et al., including Van Rhee F]. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021. PMID: 34382384.
• Yarlagadda L, Boerma M, Gundarlapalli S, [et al., including van Rhee F]. Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers. 2021 13(16). PMID: 34439174. PMCID: PMC8392190.
• Boyle EM, Rosenthal A, Ghamlouch H, [et al., including van Rhee F]. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2021. PMID: 34365473.
• Biran N, Dhakal B, Lentzsch S, [et al., including van Rhee F]. Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. EJHaem. 2021 2(3):375-384. PMID: 35844693. PMCID: PMC9175784.
• Nishimura Y, Fajgenbaum DC, Pierson SK, [et al., including van Rhee F]. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. American journal of hematology. 2021. PMID: 34265103. PMCID: PMC9642098.
• Boyle EM, Rosenthal A, Wang Y, [et al., including van Rhee F]. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British journal of haematology. 2021. PMID: 34244996.
• Mohan M, Meek JC, Meek ME, [et al., including van Rhee F]. Combinatorial Treatment for Unresectable Unicentric Castleman Disease. European journal of haematology. 2021. PMID: 34242421.
• Hájek R, Mina?ík J, Straub J, [et al., including van Rhee F]. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future oncology (London, England). 2021 17(19):2499-2512. PMID: 33769076.
• Li C, Xia J, Franqui Machin R, [et al., including van Rhee F]. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B-cell malignancies. The Journal of clinical investigation. 2021. PMID: 34061780. PMCID: PMC8279583.
• Mohan M, Szabo A, Yarlagadda N, [et al., including van Rhee F]. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. American journal of hematology. 2021. PMID: 34050985.
• Schinke CD, Boerma M, Bird JT, [et al., including van Rhee F]. PHF19 inhibition as a therapeutic target in multiple myeloma. Current research in translational medicine. 2021 69(3):103290. PMID: 33894670. PMCID: PMC8316274.
• Mitma AA, Burgess MJ, van Rhee F. Ehrlichia-induced hemophagocytic lymphohistiocytosis after autologous stem cell transplant. Transplant infectious disease : an official journal of the Transplantation Society. 2021:e13621. PMID: 33877729.
• Mohan M, Tackett A, Kumar M, [et al., including van Rhee F]. Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience. Bone. 2021 146:115876. PMID: 33556629. PMCID: PMC8627246.
• Landau HJ, Yellapantula V, Diamond BT, [et al., including van Rhee F]. Author Correction: Accelerated single cell seeding in relapsed multiple myeloma. Nature communications. 2021 12(1):591. PMID: 33473129. PMCID: PMC7817844.
• Boyle EM, Deshpande S, Tytarenko R, [et al., including van Rhee F]. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature communications. 2021 12(1):293. PMID: 33436579. PMCID: PMC7804406.
• Pierson SK, Khor JS, Ziglar J, [et al., including van Rhee F]. ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. Cell reports. Medicine. 2020 1(9):100158. PMID: 33377129. PMCID: PMC7762771.
• van Rhee F, Oksenhendler E, Srkalovic G, [et al.]. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood advances. 2020 4(23):6039-6050. PMID: 33284946. PMCID: PMC7724917.
• Danziger SA, McConnell M, Gockley J, [et al., including van Rhee F]. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS medicine. 2020 17(11):e1003323. PMID: 33147277. PMCID: PMC7641353.
• van Rhee F, Rossi JF, Simpson D, [et al.]. Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. British journal of haematology. 2020. PMID: 33128769. PMCID: PMC7820993.
• Deshpande S, Tytarenko RG, Wang Y, [et al., including van Rhee F]. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. European journal of haematology. 2020. PMID: 33107092.
• Fajgenbaum DC, Wu D, Goodman A, [et al., including van Rhee F]. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. American journal of hematology. 2020. PMID: 32894785. PMCID: PMC9547644.
• Dhodapkar MV, Sexton R, Hoering A, [et al., including Van Rhee F]. Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. PMID: 32816893. PMCID: PMC7679008.
• Choudhury SR, Ashby C, Tytarenko R, [et al., including van Rhee F]. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of hematology & oncology. 2020 13(1):108. PMID: 32762714. PMCID: PMC7409490.
• Landau HJ, Yellapantula V, Diamond BT, [et al., including van Rhee F]. Accelerated single cell seeding in relapsed multiple myeloma. Nature communications. 2020 11(1):3617. PMID: 32680998. PMCID: PMC7368016.
• Schinke C, Boyle EM, Ashby C, [et al., including van Rhee F]. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood cancer journal. 2020 10(6):70. PMID: 32555163. PMCID: PMC7303180.
• Pai RL, Japp AS, Gonzalez M, [et al., including van Rhee F]. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI insight. 2020 5(9). PMID: 32376796. PMCID: PMC7253017.
• Mohan M, Weinhold N, Schinke C, [et al., including van Rhee F]. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. British journal of haematology. 2020 189(1):67-71. PMID: 31820442.
• van Rhee F, Casper C, Voorhees PM, [et al.]. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. The Lancet. Haematology. 2020 7(3):e209-e217. PMID: 32027862.
• Nishimura KK, Barlogie B, van Rhee F, [et al.]. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood advances. 2020 4(2):422-431. PMID: 31990333. PMCID: PMC6988393.
• Boyle EM, Ashby C, Tytarenko R, [et al., including van Rhee F]. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. PMID: 31988198.
• Du Z, Weinhold N, Song GC, [et al., including Van Rhee F]. A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood advances. 2020 4(1):181-190. PMID: 31935283. PMCID: PMC6960456.
• Russell SJ, Babovic-Vuksanovic D, Bexon A, [et al., including Van Rhee F]. Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. Mayo Clinic proceedings. 2019 94(9):1834-1839. PMID: 31235278. PMCID: PMC6800178.
• Fajgenbaum DC, Langan RA, Japp AS, [et al., including van Rhee F]. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. The Journal of clinical investigation. 2019 129(10):4451-4463. PMID: 31408438. PMCID: PMC6763254.
• Sawyer JR, Tian E, Walker BA, [et al., including van Rhee F]. An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood cancer journal. 2019 9(8):62. PMID: 31399558. PMCID: PMC6689064.
• Rasche L, Alapat D, Kumar M, [et al., including van Rhee F]. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019 33(7):1713-1722. PMID: 30573775. PMCID: PMC6586541.
• van Rhee F, Stone K. Storming the Castle with TCP. Blood. 2019 133(16):1697-1698. PMID: 31000513.
• Atrash S, Dua I, Buros AF, [et al., including Van Rhee F]. FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients. Bone. 2019 121:134-138. PMID: 30244157.
• Johnsrud AJ, Johnsrud JJ, Susanibar SA, [et al., including Van Rhee F]. Infectious and immunological sequelae of daratumumab in multiple myeloma. British journal of haematology. 2019 185(1):187-189. PMID: 29974956.
• Mohan M, Susanibar-Adaniya S, Buros A, [et al., including Vanrhee F]. Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes. Transplant infectious disease : an official journal of the Transplantation Society. 2019 21(2):e13052. PMID: 30689291.
• Mehdi SJ, Johnson SK, Epstein J, [et al., including van Rhee F]. Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. British journal of haematology. 2019 184(4):578-593. PMID: 30408155. PMCID: PMC6361704.
• Ashby C, Tytarenko RG, Wang Y, [et al., including van Rhee F]. Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53. Oncotarget. 2019 10(7):732-737. PMID: 30774775. PMCID: PMC6366829.
• Morra DE, Pierson SK, Shilling D, [et al., including van Rhee F]. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. British journal of haematology. 2019 184(2):232-241. PMID: 30203839. PMCID: PMC9547643.
• Rasche L, Kumar M, Gershner G, [et al., including van Rhee F]. Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?. Theranostics. 2019 9(16):4756-4763. PMID: 31367255. PMCID: PMC6643447.
• Nabel CS, Sameroff S, Shilling D, [et al., including van Rhee F]. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PloS one. 2019 14(6):e0218660. PMID: 31242229. PMCID: PMC6594611.
• van Rhee F, Voorhees P, Dispenzieri A, [et al.]. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 132(20):2115-2124. PMID: 30181172. PMCID: PMC6238190.
• Morgan GJ, He J, Tytarenko R, [et al., including van Rhee F]. Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia. 2018 32(11):2435-2444. PMID: 29654269. PMCID: PMC6224403.
• Qiang YW, Ye S, Huang Y, [et al., including Van Rhee F]. MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma. BMC cancer. 2018 18(1):724. PMID: 29980194. PMCID: PMC6035431.
• Rasche L, Angtuaco EJ, Alpe TL, [et al., including van Rhee F]. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018 132(1):59-66. PMID: 29784643. PMCID: PMC6034645.
• Pierson SK, Stonestrom AJ, Shilling D, [et al., including van Rhee F]. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. American journal of hematology. 2018 93(7):902-912. PMID: 29675946.
• Schinke C, Qu P, Mehdi SJ, [et al., including van Rhee F]. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 24(12):2913-2919. PMID: 29563136.
• Davies FE, Rosenthal A, Rasche L, [et al., including van Rhee F]. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018 103(6):1047-1053. PMID: 29567784. PMCID: PMC6058800.
• Khan M, Stone K, van Rhee F. Daratumumab for POEMS Syndrome. Mayo Clinic proceedings. 2018 93(4):542-544. PMID: 29622102.
• Gralewski JH, Post GR, van Rhee F, Yuan Y. Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing. Diagnostic pathology. 2018 13(1):15. PMID: 29463311. PMCID: PMC5819706.
• van Rhee F, Munshi NC. Castleman Disease. Hematology/oncology clinics of North America. 2018 32(1):xiii-xiv. PMID: 29157623.
• van Rhee F, Greenway A, Stone K. Treatment of Idiopathic Castleman Disease. Hematology/oncology clinics of North America. 2018 32(1):89-106. PMID: 29157622.
• Thanendrarajan S, Tian E, Qu P, [et al., including van Rhee F]. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 102(9):e364-e367. PMID: 28550191. PMCID: PMC5685226.
• Rasche L, Chavan SS, Stephens OW, [et al., including van Rhee F]. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nature communications. 2017 8(1):268. PMID: 28814763. PMCID: PMC5559527.
• Mohan M, Buros A, Mathur P, [et al., including van Rhee F]. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. American journal of hematology. 2017 92(8):739-745. PMID: 28383130.
• Hoering A, Wang H, Carlton V, [et al., including van Rhee F]. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017 102(8):e313-e316. PMID: 28522572. PMCID: PMC5541885.
• Rasche L, Angtuaco E, McDonald JE, [et al., including van Rhee F]. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017 130(1):30-34. PMID: 28432222. PMCID: PMC5501152.
• Jethava YS, Mitchell A, Epstein J, [et al., including van Rhee F]. Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 23(11):2665-2672. PMID: 27810902. PMCID: PMC6080620.
• Mohan M, Samant RS, Yoon D, [et al., including van Rhee F]. Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2017 32(6):1261-1266. PMID: 28240368. PMCID: PMC5466479.
• McDonald JE, Kessler MM, Gardner MW, [et al., including van Rhee F]. Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 23(8):1981-1987. PMID: 27698001. PMCID: PMC5777601.
• Rasche L, Weinhold N, Morgan GJ, [et al., including van Rhee F]. Immunologic approaches for the treatment of multiple myeloma. Cancer treatment reviews. 2017 55:190-199. PMID: 28431262. PMCID: PMC5604432.
• Fajgenbaum DC, Uldrick TS, Bagg A, [et al., including van Rhee F]. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017 129(12):1646-1657. PMID: 28087540. PMCID: PMC5364342.
• Sawyer JR, Tian E, Shaughnessy JD Jr, [et al., including Van Rhee F]. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia. 2017 31(3):637-644. PMID: 27694925. PMCID: PMC6005364.
• Chavan SS, He J, Tytarenko R, [et al., including van Rhee F]. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood cancer journal. 2017 7(2):e535. PMID: 28234347. PMCID: PMC5386330.
• Qiang YW, Ye S, Chen Y, [et al., including van Rhee F]. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood. 2016 128(25):2919-2930. PMID: 27793878. PMCID: PMC5179331.
• Weinhold N, Ashby C, Rasche L, [et al., including van Rhee F]. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016 128(13):1735-44. PMID: 27516441. PMCID: PMC5043128.
• Jethava Y, Mitchell A, Zangari M, [et al., including van Rhee F]. Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood cancer journal. 2016 6:e471. PMID: 27635734. PMCID: PMC5056975.
• Jethava Y, Mitchell A, Zangari M, [et al., including van Rhee F]. Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood cancer journal. 2016 6(7):e453. PMID: 27471869. PMCID: PMC5030385.